Stocks News

LAST PRICE
28.1400
TODAY'S CHANGE (%)
Trending Up1.1200 (4.1451%)

Bid / Lots
24.1100/ 1
Ask / Lots
30.0000/ 7
Open / Previous Close
27.8790 / 27.0200
Day Range
Low 27.3400
High 28.4000
52 Week Range
Low 22.9291
High 53.1800
Volume
946,607
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 20, 2024
- Celldex Therapeutics Doses First Patient in Study of Potential Inflammatory Disease Treatment, from 8:56AM ET on Wednesday Nov 20, 2024 by MT Newswires
  8:56AM ET on Wednesday Nov 20, 2024 by MT Newswires
  Companies Mentioned: CLDX
  08:56 AM EST, 11/20/2024 (MT Newswires) -- Celldex Therapeutics (CLDX) said Wednesday that the first patient has been dosed in the company's phase 1a study of CDX-622, a potential inflammatory disease treatment, in healthy volunteers. The drug is an...
- Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases, from 8:01AM ET on Wednesday Nov 20, 2024 by Dow Jones
  8:01AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: CLDX
  
  Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
  
  HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 1a study of CDX-622 in healthy volunteers. CDX-622 is a bispecific antibody that targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation.
- DJ Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 6:21AM ET on Wednesday Nov 20, 2024 by Dow Jones
  6:21AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: CLDX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 20, 2024 06:21 ET (11:21 GMT)
Nov 11, 2024
- Celldex Therapeutics to Present at Upcoming Investor Conferences, from 4:01PM ET on Monday Nov 11, 2024 by Dow Jones
  4:01PM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: CLDX
  
  Celldex Therapeutics to Present at Upcoming Investor Conferences
  
  HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
Nov 7, 2024
- DJ Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 3:25PM ET on Thursday Nov 07, 2024 by Dow Jones
  3:25PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: CLDX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 07, 2024 15:25 ET (20:25 GMT)

Nov 21, 2024
- DJ NewAmsterdam Pharma Price Target Maintained With a $36.00/Share by Needham, from 4:42AM ET on Thursday Nov 21, 2024 by Dow Jones
  4:42AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: NAMS
Nov 20, 2024
- DJ NewAmsterdam Pharma Down Over 15%, On Track for Largest Percent Decrease Since June 2023 -- Data Talk, from 2:33PM ET on Wednesday Nov 20, 2024 by Dow Jones
  2:33PM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: NAMS
- NewAmsterdam Pharma's Anti-Bad Cholesterol Treatment Combination Meets Targets in Phase 3 Trial, from 9:33AM ET on Wednesday Nov 20, 2024 by MT Newswires
  9:33AM ET on Wednesday Nov 20, 2024 by MT Newswires
  Companies Mentioned: NAMS
- DJ NewAmsterdam Pharma Phase 3 Drug Combo Study Hits Main Endpoints, from 7:35AM ET on Wednesday Nov 20, 2024 by Dow Jones
  7:35AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: NAMS
- NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH, from 7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
  7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: NAMS
Nov 18, 2024
- NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024, from 3:20PM ET on Monday Nov 18, 2024 by Dow Jones
  3:20PM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: NAMS
Nov 15, 2024
- Structure Therapeutics to Participate in the Jefferies London Healthcare Conference, from 8:30AM ET on Friday Nov 15, 2024 by Dow Jones
  8:30AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: GPCR
- DJ Tarsus Pharmaceuticals Is Maintained at Neutral by Goldman Sachs, from 6:57AM ET on Friday Nov 15, 2024 by Dow Jones
  6:57AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: TARS
Nov 14, 2024
- Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating, from 8:35AM ET on Thursday Nov 14, 2024 by MT Newswires
  8:35AM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: TARS
- DJ Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer, from 8:26AM ET on Thursday Nov 14, 2024 by Dow Jones
  8:26AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: TARS

Celldex Therapeutics Inc
NASDAQ:CLDXUnited States

Search Criteria

Nov 20, 2024

Celldex Therapeutics Doses First Patient in Study of Potential Inflammatory Disease Treatment, from 8:56AM ET on Wednesday Nov 20, 2024 by MT Newswires

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases, from 8:01AM ET on Wednesday Nov 20, 2024 by Dow Jones

DJ Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 6:21AM ET on Wednesday Nov 20, 2024 by Dow Jones

Nov 11, 2024

Celldex Therapeutics to Present at Upcoming Investor Conferences, from 4:01PM ET on Monday Nov 11, 2024 by Dow Jones

Nov 7, 2024

DJ Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 3:25PM ET on Thursday Nov 07, 2024 by Dow Jones

Peers Headlines

Nov 21, 2024

DJ NewAmsterdam Pharma Price Target Maintained With a $36.00/Share by Needham, from 4:42AM ET on Thursday Nov 21, 2024 by Dow Jones

Nov 20, 2024

DJ NewAmsterdam Pharma Down Over 15%, On Track for Largest Percent Decrease Since June 2023 -- Data Talk, from 2:33PM ET on Wednesday Nov 20, 2024 by Dow Jones

NewAmsterdam Pharma's Anti-Bad Cholesterol Treatment Combination Meets Targets in Phase 3 Trial, from 9:33AM ET on Wednesday Nov 20, 2024 by MT Newswires

DJ NewAmsterdam Pharma Phase 3 Drug Combo Study Hits Main Endpoints, from 7:35AM ET on Wednesday Nov 20, 2024 by Dow Jones

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH, from 7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones

Nov 18, 2024

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024, from 3:20PM ET on Monday Nov 18, 2024 by Dow Jones

Nov 15, 2024

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference, from 8:30AM ET on Friday Nov 15, 2024 by Dow Jones

DJ Tarsus Pharmaceuticals Is Maintained at Neutral by Goldman Sachs, from 6:57AM ET on Friday Nov 15, 2024 by Dow Jones

Nov 14, 2024

Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating, from 8:35AM ET on Thursday Nov 14, 2024 by MT Newswires

DJ Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer, from 8:26AM ET on Thursday Nov 14, 2024 by Dow Jones